Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederik E Deiman

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Current Heart Failure Reports|June 14, 2022
Review: Precision Medicine Approaches for Genetic Cardiomyopathy: Targeting Phospholamban R14delFrederik E Deiman, Nils Bomer, Peter van der Meer, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|March 6, 2025
Identification of disease-specific pathways and modifiers in phospholamban R14del cardiomyopathy: rationale, design and baseline characteristics of DECIPHER-PLN cohortFrederik E Deiman, Remco de Brouwer, Lukas Baumhove, et al.
Journal of Cardiovascular Translational Research|October 30, 2025
RNA Therapeutics in Heart FailureFrederik E Deiman, Myrthe M de Graaf, Herman H W Sillje, et al.
Cardiovascular Research|April 25, 2026
Plasma proteomics stratification identifies phospholamban R14del carriers at risk for disease progressionFrederik E Deiman, Taner Arslan, Remco de Brouwer, et al.
ESC Heart Failure|July 20, 2024
IL-17 is associated with disease severity and targetable inflammatory processes in heart failureLukas Baumhove, Bart J van Essen, Martin M Dokter, et al.
International Journal of Molecular Sciences|November 13, 2021
Selenoprotein DIO2 Is a Regulator of Mitochondrial Function, Morphology and UPRmt in Human CardiomyocytesNils Bomer, Mario G Pavez-Giani, Frederik E Deiman, et al.
Signal Transduction and Targeted Therapy|May 27, 2026
Phosphoproteomics distinguishes disease-specific mechanisms for human phospholamban cardiomyopathy reversible by RNA therapyFrederik E Deiman, Nils Bömer, Pia Davidsson, et al.
JACC. Cardiooncology|July 3, 2023
Evaluation of Senescence and Its Prevention in Doxorubicin-Induced Cardiotoxicity Using Dynamic Engineered Heart TissuesAnnet N Linders, Itamar B Dias, Ekaterina S Ovchinnikova, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Current Heart Failure Reports|June 14, 2022
Review: Precision Medicine Approaches for Genetic Cardiomyopathy: Targeting Phospholamban R14delFrederik E Deiman, Nils Bomer, Peter van der Meer, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|March 6, 2025
Identification of disease-specific pathways and modifiers in phospholamban R14del cardiomyopathy: rationale, design and baseline characteristics of DECIPHER-PLN cohortFrederik E Deiman, Remco de Brouwer, Lukas Baumhove, et al.
Journal of Cardiovascular Translational Research|October 30, 2025
RNA Therapeutics in Heart FailureFrederik E Deiman, Myrthe M de Graaf, Herman H W Sillje, et al.
Cardiovascular Research|April 25, 2026
Plasma proteomics stratification identifies phospholamban R14del carriers at risk for disease progressionFrederik E Deiman, Taner Arslan, Remco de Brouwer, et al.
ESC Heart Failure|July 20, 2024
IL-17 is associated with disease severity and targetable inflammatory processes in heart failureLukas Baumhove, Bart J van Essen, Martin M Dokter, et al.
International Journal of Molecular Sciences|November 13, 2021
Selenoprotein DIO2 Is a Regulator of Mitochondrial Function, Morphology and UPRmt in Human CardiomyocytesNils Bomer, Mario G Pavez-Giani, Frederik E Deiman, et al.
Signal Transduction and Targeted Therapy|May 27, 2026
Phosphoproteomics distinguishes disease-specific mechanisms for human phospholamban cardiomyopathy reversible by RNA therapyFrederik E Deiman, Nils Bömer, Pia Davidsson, et al.
JACC. Cardiooncology|July 3, 2023
Evaluation of Senescence and Its Prevention in Doxorubicin-Induced Cardiotoxicity Using Dynamic Engineered Heart TissuesAnnet N Linders, Itamar B Dias, Ekaterina S Ovchinnikova, et al.
Pageof 1